vs
Side-by-side financial comparison of Enhabit, Inc. (EHAB) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
Enhabit, Inc. is the larger business by last-quarter revenue ($270.4M vs $245.3M, roughly 1.1× Tecnoglass Inc.). Tecnoglass Inc. runs the higher net margin — 10.6% vs -14.3%, a 25.0% gap on every dollar of revenue. On growth, Enhabit, Inc. posted the faster year-over-year revenue change (4.7% vs 2.4%). Tecnoglass Inc. produced more free cash flow last quarter ($11.4M vs $3.3M). Over the past eight quarters, Tecnoglass Inc.'s revenue compounded faster (12.8% CAGR vs 1.5%).
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
EHAB vs TGLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.4M | $245.3M |
| Net Profit | $-38.7M | $26.1M |
| Gross Margin | — | 40.0% |
| Operating Margin | -12.3% | 18.3% |
| Net Margin | -14.3% | 10.6% |
| Revenue YoY | 4.7% | 2.4% |
| Net Profit YoY | 15.9% | -44.5% |
| EPS (diluted) | $-0.76 | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.4M | $245.3M | ||
| Q3 25 | $263.6M | $260.5M | ||
| Q2 25 | $266.1M | $255.5M | ||
| Q1 25 | $259.9M | $222.3M | ||
| Q4 24 | $258.2M | $239.6M | ||
| Q3 24 | $253.6M | $238.3M | ||
| Q2 24 | $260.6M | $219.7M | ||
| Q1 24 | $262.4M | $192.6M |
| Q4 25 | $-38.7M | $26.1M | ||
| Q3 25 | $11.1M | $47.2M | ||
| Q2 25 | $5.2M | $44.1M | ||
| Q1 25 | $17.8M | $42.2M | ||
| Q4 24 | $-46.0M | $47.0M | ||
| Q3 24 | $-110.2M | $49.5M | ||
| Q2 24 | $-200.0K | $35.0M | ||
| Q1 24 | $200.0K | $29.7M |
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | 43.9% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 40.8% | ||
| Q1 24 | — | 38.8% |
| Q4 25 | -12.3% | 18.3% | ||
| Q3 25 | 6.4% | 25.1% | ||
| Q2 25 | 6.3% | 24.0% | ||
| Q1 25 | 6.1% | 26.7% | ||
| Q4 24 | -16.0% | 28.0% | ||
| Q3 24 | -38.6% | 28.4% | ||
| Q2 24 | 4.3% | 23.3% | ||
| Q1 24 | 4.9% | 21.3% |
| Q4 25 | -14.3% | 10.6% | ||
| Q3 25 | 4.2% | 18.1% | ||
| Q2 25 | 2.0% | 17.3% | ||
| Q1 25 | 6.8% | 19.0% | ||
| Q4 24 | -17.8% | 19.6% | ||
| Q3 24 | -43.5% | 20.8% | ||
| Q2 24 | -0.1% | 15.9% | ||
| Q1 24 | 0.1% | 15.4% |
| Q4 25 | $-0.76 | $0.57 | ||
| Q3 25 | $0.22 | $1.01 | ||
| Q2 25 | $0.10 | $0.94 | ||
| Q1 25 | $0.35 | $0.90 | ||
| Q4 24 | $-0.92 | $1.00 | ||
| Q3 24 | $-2.20 | $1.05 | ||
| Q2 24 | $0.00 | $0.75 | ||
| Q1 24 | $0.01 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $43.6M | $104.1M |
| Total DebtLower is stronger | $426.0M | $174.4M |
| Stockholders' EquityBook value | $534.0M | $713.1M |
| Total Assets | $1.2B | $1.3B |
| Debt / EquityLower = less leverage | 0.80× | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.6M | $104.1M | ||
| Q3 25 | $56.9M | $127.1M | ||
| Q2 25 | $37.1M | $140.9M | ||
| Q1 25 | $39.5M | $160.2M | ||
| Q4 24 | $28.4M | $137.5M | ||
| Q3 24 | $45.7M | $124.8M | ||
| Q2 24 | $28.5M | $129.5M | ||
| Q1 24 | $36.5M | $138.8M |
| Q4 25 | $426.0M | $174.4M | ||
| Q3 25 | $441.5M | $114.7M | ||
| Q2 25 | $456.9M | $110.6M | ||
| Q1 25 | $467.3M | $110.6M | ||
| Q4 24 | $492.6M | $111.1M | ||
| Q3 24 | $502.9M | $126.8M | ||
| Q2 24 | $512.7M | $144.7M | ||
| Q1 24 | $526.7M | $160.9M |
| Q4 25 | $534.0M | $713.1M | ||
| Q3 25 | $566.8M | $764.0M | ||
| Q2 25 | $552.4M | $736.0M | ||
| Q1 25 | $543.2M | $685.1M | ||
| Q4 24 | $523.5M | $631.2M | ||
| Q3 24 | $566.1M | $613.3M | ||
| Q2 24 | $674.3M | $574.8M | ||
| Q1 24 | $672.3M | $573.6M |
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $1.3B | $996.3M | ||
| Q2 24 | $1.4B | $942.5M | ||
| Q1 24 | $1.4B | $981.6M |
| Q4 25 | 0.80× | 0.24× | ||
| Q3 25 | 0.78× | 0.15× | ||
| Q2 25 | 0.83× | 0.15× | ||
| Q1 25 | 0.86× | 0.16× | ||
| Q4 24 | 0.94× | 0.18× | ||
| Q3 24 | 0.89× | 0.21× | ||
| Q2 24 | 0.76× | 0.25× | ||
| Q1 24 | 0.78× | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.4M | $31.0M |
| Free Cash FlowOCF − Capex | $3.3M | $11.4M |
| FCF MarginFCF / Revenue | 1.2% | 4.7% |
| Capex IntensityCapex / Revenue | 0.4% | 8.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $65.8M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.4M | $31.0M | ||
| Q3 25 | $37.8M | $40.0M | ||
| Q2 25 | $10.6M | $17.9M | ||
| Q1 25 | $17.9M | $46.9M | ||
| Q4 24 | $-4.1M | $61.1M | ||
| Q3 24 | $28.4M | $41.5M | ||
| Q2 24 | $9.6M | $34.5M | ||
| Q1 24 | $17.3M | $33.4M |
| Q4 25 | $3.3M | $11.4M | ||
| Q3 25 | $36.2M | $21.2M | ||
| Q2 25 | $8.7M | $-14.7M | ||
| Q1 25 | $17.6M | $16.5M | ||
| Q4 24 | $-4.7M | $35.4M | ||
| Q3 24 | $27.7M | $17.8M | ||
| Q2 24 | $8.9M | $14.2M | ||
| Q1 24 | $15.5M | $23.6M |
| Q4 25 | 1.2% | 4.7% | ||
| Q3 25 | 13.7% | 8.2% | ||
| Q2 25 | 3.3% | -5.7% | ||
| Q1 25 | 6.8% | 7.4% | ||
| Q4 24 | -1.8% | 14.8% | ||
| Q3 24 | 10.9% | 7.5% | ||
| Q2 24 | 3.4% | 6.5% | ||
| Q1 24 | 5.9% | 12.2% |
| Q4 25 | 0.4% | 8.0% | ||
| Q3 25 | 0.6% | 7.2% | ||
| Q2 25 | 0.7% | 12.7% | ||
| Q1 25 | 0.1% | 13.7% | ||
| Q4 24 | 0.2% | 10.7% | ||
| Q3 24 | 0.3% | 9.9% | ||
| Q2 24 | 0.3% | 9.2% | ||
| Q1 24 | 0.7% | 5.1% |
| Q4 25 | — | 1.19× | ||
| Q3 25 | 3.41× | 0.85× | ||
| Q2 25 | 2.04× | 0.41× | ||
| Q1 25 | 1.01× | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | 86.50× | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
